Evaluation of Pharmacokinetic–Pharmacodynamic Modeling for Optimizing Antimicrobial Therapy in Hospitalized Patients

Project Abstract

This study investigates the integration of pharmacokinetic–pharmacodynamic (PK-PD) modeling into antimicrobial therapy optimization for hospitalized patients, aiming to enhance therapeutic efficacy while minimizing toxicity and antimicrobial resistance. By combining population PK models with PD targets such as time above MIC for beta-lactams or AUC/MIC ratios for vancomycin and fluoroquinolones, the research develops a decision-support framework that translates patient-specific data into individualized dosing regimens. A robust literature synthesis identifies gaps in current dosing practices, highlighting variability in drug exposure due to factors like organ function, age, critical illness, and concomitant therapies. The methodology encompasses model development, external validation, and prospective simulation studies using retrospective patient data from diverse hospital settings. Population PK models are built for selected antimicrobials with rich therapeutic drug monitoring (TDM) data, incorporating covariates such as renal function, hepatic status, body weight, and illness severity scores. PD targets are defined based on pathogen-specific susceptibility profiles and infection sites, enabling the derivation of dosing strategies that maximize probability of target attainment (PTA) and reduce the risk of nephrotoxicity and hepatotoxicity. The study also evaluates the clinical impact of PK-PD–guided dosing on clinical outcomes, including time to resolution of infection, length of stay, microbiological eradication, recurrence rates, and mortality, through simulated and, where feasible, real-world implementation in antimicrobial stewardship programs. Advanced modeling techniques, including nonlinear mixed-effects modeling (NLME), Bayesian forecasting, and Monte Carlo simulations, are employed to quantify parameter uncertainty and to compare conventional dosing regimens against PK-PD–optimized regimens under various clinical scenarios. The research explores the practical considerations of deploying PK-PD tools in real-time practice, such as integration with electronic health records, data quality, TDM turnaround times, and clinician interpretability. Economic evaluations accompany clinical analyses to assess cost-effectiveness, considering drug costs, adverse event management, length of stay, and resistance burden. Sensitivity analyses examine robustness to missing data and model misspecification, while external validation across multiple hospitals ensures generalizability. The anticipated outcomes include demonstrated improvements in PTA for key antimicrobials, enhanced target attainment in critically ill subpopulations, and a framework for scalable implementation within hospital antimicrobial stewardship programs. Ethical considerations, data privacy, and regulatory compliance are addressed throughout the study design. By delivering actionable, patient-centered dosing recommendations, this research seeks to bridge the gap between PK-PD theory and bedside practice, contributing to optimized antimicrobial use, improved patient outcomes, and a sustainable approach to mitigating antimicrobial resistance in hospital settings.

Project Overview

What This Project Is About

---

A plain-language overview of how drugs move through the body (pharmacokinetics) and how the body’s response to those drugs changes over time (pharmacodynamics) are studied together to improve how antimicrobial therapy is used in hospital patients. The project explains how mathematical models can help predict the best doses, timing, and duration to kill infections while reducing side effects and resistance.

---

---

The Problem It Addresses

---

Many hospital patients receive antimicrobials with fixed dosing that may not fit individual differences in weight, organ function, or infection. This can lead to underdosing (ineffective treatment) or overdosing (toxicity). The project looks at a modeling approach to tailor therapy to each patient and infection, aiming for safer, more effective care.

---

---

Objectives of the Project

---

1. Explain the basic idea of pharmacokinetics and pharmacodynamics in simple terms.
2. Describe how models are built to relate drug dose, exposure, and effect.
3. Show how these models can guide antimicrobial dosing in hospital settings.
4. Assess potential benefits such as better cure rates and fewer side effects.
5. Identify practical challenges in applying modeling to real patients.

---

---

What You Will Do Step by Step

---

1. Review easy-to-understand literature on PK/PD concepts and antimicrobial use.
2. Summarize common modeling approaches with simple examples.
3. Discuss data sources needed for models ( patient measurements, dosing records ).
4. Explain how models are validated in practice.
5. Compare fixed-dose strategies to model-informed dosing in theory.

---

---

Expected Outcome

Clear, student-friendly understanding of how PK/PD modeling could improve antimicrobial therapy in hospitals, plus a simple outline of benefits and limitations for real-world use.